Covid19 Clinical Trial
— ICEOfficial title:
Influence of Ice Swimming on Hardening Against SARS-CoV-2 and Influence of AB0 Rh Blood Type on Viral Resistance in Polish Ice Swimmers.
Verified date | April 2021 |
Source | Wroclaw Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections. In the face of the current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic causing Coronavirus Disease 2019 (COVID-19), researchers decided to use a survey to check the incidence of COVID-19 among Polish ice swimmers, as well as recent ailments. Then, the researchers will compare the obtained results with epidemiological data for Poland.Researchers will also investigate the relationship between susceptibility to SARS-CoV-2 infection and the blood group and Rh factor among ice swimmers.
Status | Completed |
Enrollment | 2534 |
Est. completion date | March 1, 2021 |
Est. primary completion date | January 17, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - ice swimmers Exclusion Criteria: - not active ice swimmers |
Country | Name | City | State |
---|---|---|---|
Poland | Department of Radiotherapy of Multidisciplinary Provincial Hospital | Gorzów Wielkopolski | Lubuskie |
Poland | Department of Public Health at Wroclaw Medical University | Wroclaw | Dolny Slask |
Poland | Treasury Medical Company | Zielona Góra | Lubuskie |
Lead Sponsor | Collaborator |
---|---|
Wroclaw Medical University |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the incidence of COVID-19 among ice swimmers compared to the general population. | Comparison of the data obtained from surveys collected among ice swimmers with the data published in official channels for the general population during this period. | 47 days. | |
Primary | Assessment of the frequency of asymptomatic SARS-CoV-2 infection among ice swimmers compared to the general population. | Comparison of the data obtained from surveys collected among ice swimmers with the data published in official channels for the general population during this period. | 47 days. | |
Primary | Assessment of the frequency of occurrence of particular symptoms of SARS-CoV-2 infection among ice swimmers compared to the general population. | Comparison of the data obtained from surveys collected among ice swimmers with the data published in official channels for the general population during this period. | 47 days. | |
Primary | Assessment of the frequency of COVID-19 treatment in an outpatient, inpatient and intensive care unit among ice swimmers compared to the general population. | Comparison of the data obtained from surveys collected among ice swimmers with the data published in official channels for the general population during this period. | 47 days. | |
Primary | Assessment of the impact of parameters and ice swimming strategies on the likelihood of developing COVID-19, the occurrence of individual symptoms of the disease and the severity of its course. | Inference from data obtained from surveys collected among ice swimmers. | 47 days. | |
Primary | Assessment of the influence of blood group on susceptibility to SARS-CoV-2 infection among ice swimmers. | Inference from data obtained from surveys collected among ice swimmers. | 47 days. | |
Secondary | Assessment of the immunity of the ice swimmer's immune system compared to the general population. | Comparison of the data obtained from surveys collected among ice swimmers with the data published in official channels for the general population during this period. | 47 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |